Aldeyra Therapeutics shares pop on positive trial results for dry eye disease drug
Shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) are popping in Wednesday’s pre-market session in response to its announcement of positive results from a Phase 2b trial evaluating its drug topical ocular reproxalap in patients with dry eye disease.
Patients who received a 0.25% concentration of reproxalap showed statistically significant reductions in the Four-Symptom Ocular Dryness score (p<0.05) and the Overall Ocular Discomfort Symptom score (p<0.05). Symptom improvement measured against a placebo was observed across all measures, according to the company.
Investors welcomed the results, sending Aldeyra shares up 32% in Wednesday’s pre-market session to $13.10.
On the back of the successful Phase 2b results, Aldeyra plans to introduce a Phase 3 program for dry eye disease next year, pending discussions with US regulators.
Read: Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease
“The addition of dry eye disease to our late-stage clinical portfolio, which includes Phase 3 clinical trials in allergic conjunctivitis and noninfectious anterior uveitis, highlights the potential of reproxalap as a highly differentiated and novel ophthalmic therapy,” noted Aldeyra CEO Todd Brady.
Dry eye disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, which leads to dryness and inflammation, and in severe cases, permanent vision impairment.
The three-hundred patients taking part in the Phase 2b trial received either a 0.1% or 0.25% concentration of reproxalap or a placebo for twelve weeks. Patients receiving both 0.1% and 0.25% reproxalap concentrations saw improvement in their conditions.
Topical ocular reproxalap was well tolerated and reported adverse events were generally mild.
Based in Lexington, Massachusetts, Aldeyra is also developing drugs for autoimmune disease, retinal inflammation, metabolic disease and cancer.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/205767/aldeyra-therapeutics-shares-pop-on-positive-trial-results-for-dry-eye-disease-drug-205767.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).